Biocon Limited has informed the Exchange regarding a press release dated August 31, 2020, titled "Biocon Biologics and Mylan Announce Launch of Semglee (insulin glargine injection) in the U.S. to Expand Access for Patients Living with Diabetes.".
Press Release Aug 31 2020
Filed with NSE ·
6ix hasn’t read this filing yet.
Later from Biocon
- Press Release Oct 08 2020
- Press Release Oct 23 2020
- Press Release Oct 30 2020
- Press Release Nov 07 2020
- Press Release Dec 15 2020
Follow Biocon into a list and get an email when it puts out news.
Follow Biocon